-
AOT 2026 | Professor Matthias Stelljes: Therapeutic Pathways and Key Decision-Making Considerations in Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia
To comprehensively improve public health and strengthen strategies for the prevention and treatment of major diseases, medical innovation and international collaboration have become key drivers of clinical progress. Against this backdrop, the 2026 Beijing International Hematopoietic Stem Cell Transplantation Conference (AOT) was successfully held in Beijing from April 24 to 25, 2026. Organized by the…
-
AOT 2026 | Professor Donal P. McLornan: Challenges, Strategies, and Future Directions for Hematopoietic Stem Cell Transplantation in MDS/MPN
To comprehensively improve public health and strengthen strategies for the prevention and treatment of major diseases, medical innovation and international collaboration have become key drivers of clinical progress. Against this backdrop, the 2026 Beijing International Hematopoietic Stem Cell Transplantation Conference (AOT) was successfully held in Beijing from April 24 to 25, 2026. Organized by the…
-
CSCO Guideline Preview | Professor Cuijian Zhang: Six Years of Evolution in the Urothelial Carcinoma Guidelines as ADCs and Novel Therapies Further Reshape Clinical Practice
With the continuous emergence of novel therapies and landmark clinical evidence, the treatment landscape of urothelial carcinoma is undergoing profound transformation. Ahead of the 2026 Chinese Society of Clinical Oncology (CSCO) Guidelines Conference, Oncology Frontier – UroStream presents a special series of expert previews on major genitourinary oncology guidelines. In this issue, Professor Cuijian Zhang…
-
Old Drug, New Use! Professor Kan Gong’s Team from Peking University First Hospital Collaborates with International Experts to Propose a Novel Combination Strategy for Renal Cell Carcinoma
Renal cell carcinoma (RCC) is one of the most common malignant tumors of the urinary system, among which approximately 75% are clear cell renal cell carcinoma (ccRCC). Loss of the VHL gene is the key molecular event driving this disease. VHL inactivation places tumor cells in a persistent state of “pseudohypoxia,” continuously activating HIF-2α-centered oncogenic…
-
Chronicles of Genitourinary Oncology · 2026 | Led by Professor Jun Guo, Experts Highlight the Year’s Landmark Breakthroughs in Genitourinary Cancer Care (Part II)
From the first glimmer of insight in 1941, when Professor Charles Huggins discovered the hormone dependence of prostate cancer, to today’s flourishing era of precision oncology, the field of genitourinary cancers has traveled an extraordinary path—from silence and therapeutic limitation to an age of precision-driven breakthroughs. As both a participant in and witness to this…
-
Urologic Oncology Chronicle 2026 | Professor Jun Guo and Leading Experts Highlight the Landmark Advances Reshaping GU Oncology
From the moment Charles Huggins first demonstrated the hormone dependence of prostate cancer in 1941, genitourinary oncology has evolved from an era of limited treatment possibilities into one defined by precision medicine and therapeutic innovation.
Connecting Medical Expertise through Media
